Cargando…
Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report
Alpelisib plus fulvestrant is a valid second or advanced line of treatment for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who harbor an activating PIK3CA mutation. The well-known side effects of alpelisib are hyperglycemia, rash, and diarrhea. Herein, we rep...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642942/ https://www.ncbi.nlm.nih.gov/pubmed/37965451 http://dx.doi.org/10.3389/fonc.2023.1255832 |